際際滷shows by User: LMBeharry / http://www.slideshare.net/images/logo.gif 際際滷shows by User: LMBeharry / Sat, 01 Apr 2023 14:06:49 GMT 際際滷Share feed for 際際滷shows by User: LMBeharry 2022-03-31_GILD-MC-ValuationReport_Draft03_Signed.pdf /slideshow/20220331gildmcvaluationreportdraft03signedpdf/257075771 2022-03-31gild-mc-valuationreportdraft03signed-230401140649-e4fe7055
Gilead Sciences, Inc. Equity Valuation; Monte Carlo and Static DCF Models; Full Report with Quantitative and Qualitative Analysis; Remdesivir]]>
Gilead Sciences, Inc. Equity Valuation; Monte Carlo and Static DCF Models; Full Report with Quantitative and Qualitative Analysis; Remdesivir]]> Sat, 01 Apr 2023 14:06:49 GMT /slideshow/20220331gildmcvaluationreportdraft03signedpdf/257075771 LMBeharry@slideshare.net(LMBeharry) 2022-03-31_GILD-MC-ValuationReport_Draft03_Signed.pdf LMBeharry Gilead Sciences, Inc. Equity Valuation; Monte Carlo and Static DCF Models; Full Report with Quantitative and Qualitative Analysis; Remdesivir <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/2022-03-31gild-mc-valuationreportdraft03signed-230401140649-e4fe7055-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> Gilead Sciences, Inc. Equity Valuation; Monte Carlo and Static DCF Models; Full Report with Quantitative and Qualitative Analysis; Remdesivir
2022-03-31_GILD-MC-ValuationReport_Draft03_Signed.pdf from Lyndon Martin W. Beharry
]]> 9 0 https://cdn.slidesharecdn.com/ss_thumbnails/2022-03-31gild-mc-valuationreportdraft03signed-230401140649-e4fe7055-thumbnail.jpg?width=120&height=120&fit=bounds document Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 2016_IMPC_UB-Proceedings-pdf.pdf /slideshow/2016impcubproceedingspdfpdf/255803795 2016impcub-proceedings-pdf-230210144633-352ea1a6
Beharry, Lyndon Mw: Oyu Tolgoi article appears on page 251 (247 in the PDF file) International Minerals Processing Conference Ulaanbaatar Mongolia 2016 ]]>
Beharry, Lyndon Mw: Oyu Tolgoi article appears on page 251 (247 in the PDF file) International Minerals Processing Conference Ulaanbaatar Mongolia 2016 ]]> Fri, 10 Feb 2023 14:46:33 GMT /slideshow/2016impcubproceedingspdfpdf/255803795 LMBeharry@slideshare.net(LMBeharry) 2016_IMPC_UB-Proceedings-pdf.pdf LMBeharry Beharry, Lyndon Mw: Oyu Tolgoi article appears on page 251 (247 in the PDF file) International Minerals Processing Conference Ulaanbaatar Mongolia 2016 <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/2016impcub-proceedings-pdf-230210144633-352ea1a6-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> Beharry, Lyndon Mw: Oyu Tolgoi article appears on page 251 (247 in the PDF file) International Minerals Processing Conference Ulaanbaatar Mongolia 2016
2016_IMPC_UB-Proceedings-pdf.pdf from Lyndon Martin W. Beharry
]]> 34 0 https://cdn.slidesharecdn.com/ss_thumbnails/2016impcub-proceedings-pdf-230210144633-352ea1a6-thumbnail.jpg?width=120&height=120&fit=bounds document Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 2022-08-21_LANC_Equity-Valuation_1MM-Trials.pdf /slideshow/20220821lancequityvaluation1mmtrialspdf/252632901 2022-08-21lancequity-valuation1mm-trials-220821150159-43867f1b
Lancaster Colony Corporation is one of my favorite equities: Stable, stable, stable. Lancaster Colony is my *GoTo* example for teaching Corporate Finance. In my limited estimation, Lancaster is one of the few, most visible publicly-traded American companies boasting clean financials, little or no debt, excellent corporate governance, and a balanced executive pay schedule. You cannot get more wholesome than Lancaster. The very name suggests Amish lifestyle, thrift and savings, and quality home-spun products. I've been following Lancaster since I was an MBA candidate in 1995. I updated my Excel Monte Carlo valuation workbook with Lancaster financials since 2018 to provide a more current Equity Value range. But this conservative analysis propels the firm's pro-forma at a mere 0.00% growth rate in revenue - so it is a low-ball estimate based on the close of books June 30, 2021. I expect LANC will release its 2022 10K late in the week beginning Monday 22 August 2022. Once I review the more current financials, I will complete a valuation with an alternative growth schedule. Lancaster Colony is based in Ohio, a state with poison pill legislation within the State Code. Lancaster is also closely held and thinly traded. Hence, LANC is virtually immune from hostile takeover.]]>
Lancaster Colony Corporation is one of my favorite equities: Stable, stable, stable. Lancaster Colony is my *GoTo* example for teaching Corporate Finance. In my limited estimation, Lancaster is one of the few, most visible publicly-traded American companies boasting clean financials, little or no debt, excellent corporate governance, and a balanced executive pay schedule. You cannot get more wholesome than Lancaster. The very name suggests Amish lifestyle, thrift and savings, and quality home-spun products. I've been following Lancaster since I was an MBA candidate in 1995. I updated my Excel Monte Carlo valuation workbook with Lancaster financials since 2018 to provide a more current Equity Value range. But this conservative analysis propels the firm's pro-forma at a mere 0.00% growth rate in revenue - so it is a low-ball estimate based on the close of books June 30, 2021. I expect LANC will release its 2022 10K late in the week beginning Monday 22 August 2022. Once I review the more current financials, I will complete a valuation with an alternative growth schedule. Lancaster Colony is based in Ohio, a state with poison pill legislation within the State Code. Lancaster is also closely held and thinly traded. Hence, LANC is virtually immune from hostile takeover.]]> Sun, 21 Aug 2022 15:01:58 GMT /slideshow/20220821lancequityvaluation1mmtrialspdf/252632901 LMBeharry@slideshare.net(LMBeharry) 2022-08-21_LANC_Equity-Valuation_1MM-Trials.pdf LMBeharry Lancaster Colony Corporation is one of my favorite equities: Stable, stable, stable. Lancaster Colony is my *GoTo* example for teaching Corporate Finance. In my limited estimation, Lancaster is one of the few, most visible publicly-traded American companies boasting clean financials, little or no debt, excellent corporate governance, and a balanced executive pay schedule. You cannot get more wholesome than Lancaster. The very name suggests Amish lifestyle, thrift and savings, and quality home-spun products. I've been following Lancaster since I was an MBA candidate in 1995. I updated my Excel Monte Carlo valuation workbook with Lancaster financials since 2018 to provide a more current Equity Value range. But this conservative analysis propels the firm's pro-forma at a mere 0.00% growth rate in revenue - so it is a low-ball estimate based on the close of books June 30, 2021. I expect LANC will release its 2022 10K late in the week beginning Monday 22 August 2022. Once I review the more current financials, I will complete a valuation with an alternative growth schedule. Lancaster Colony is based in Ohio, a state with poison pill legislation within the State Code. Lancaster is also closely held and thinly traded. Hence, LANC is virtually immune from hostile takeover. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/2022-08-21lancequity-valuation1mm-trials-220821150159-43867f1b-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> Lancaster Colony Corporation is one of my favorite equities: Stable, stable, stable. Lancaster Colony is my *GoTo* example for teaching Corporate Finance. In my limited estimation, Lancaster is one of the few, most visible publicly-traded American companies boasting clean financials, little or no debt, excellent corporate governance, and a balanced executive pay schedule. You cannot get more wholesome than Lancaster. The very name suggests Amish lifestyle, thrift and savings, and quality home-spun products. I&#39;ve been following Lancaster since I was an MBA candidate in 1995. I updated my Excel Monte Carlo valuation workbook with Lancaster financials since 2018 to provide a more current Equity Value range. But this conservative analysis propels the firm&#39;s pro-forma at a mere 0.00% growth rate in revenue - so it is a low-ball estimate based on the close of books June 30, 2021. I expect LANC will release its 2022 10K late in the week beginning Monday 22 August 2022. Once I review the more current financials, I will complete a valuation with an alternative growth schedule. Lancaster Colony is based in Ohio, a state with poison pill legislation within the State Code. Lancaster is also closely held and thinly traded. Hence, LANC is virtually immune from hostile takeover.
2022-08-21_LANC_Equity-Valuation_1MM-Trials.pdf from Lyndon Martin W. Beharry
]]> 2 0 https://cdn.slidesharecdn.com/ss_thumbnails/2022-08-21lancequity-valuation1mm-trials-220821150159-43867f1b-thumbnail.jpg?width=120&height=120&fit=bounds document Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 2022-07-28_LMT-MC-ValuationReport_Draft03.pdf /slideshow/20220728lmtmcvaluationreportdraft03pdf/252349063 2022-07-28lmt-mc-valuationreportdraft03-220728135603-45ba029d
2022-07-28 I present the final draft of my professional valuation of Lockheed Martin Corporation Equity per Share. I spent some hours cleaning up the prose (mostly light editing). I checked the citations, added "C-5" to Lockheed's notable creations, and worked to tighten up the grammar. As always, subsequent readings will inevitably reveal typographical and grammatical errors, but in general, this report is complete. I welcome any suggestions or complaints. Feedback always helps me improve my writing and my analysis. (I will be transitioning to work on a write-up on Gilead Sciences starting next week. From time to time I like to brush up on my biochemistry, molecular biology, and Phase Trial Studies.)]]>
2022-07-28 I present the final draft of my professional valuation of Lockheed Martin Corporation Equity per Share. I spent some hours cleaning up the prose (mostly light editing). I checked the citations, added "C-5" to Lockheed's notable creations, and worked to tighten up the grammar. As always, subsequent readings will inevitably reveal typographical and grammatical errors, but in general, this report is complete. I welcome any suggestions or complaints. Feedback always helps me improve my writing and my analysis. (I will be transitioning to work on a write-up on Gilead Sciences starting next week. From time to time I like to brush up on my biochemistry, molecular biology, and Phase Trial Studies.)]]> Thu, 28 Jul 2022 13:56:02 GMT /slideshow/20220728lmtmcvaluationreportdraft03pdf/252349063 LMBeharry@slideshare.net(LMBeharry) 2022-07-28_LMT-MC-ValuationReport_Draft03.pdf LMBeharry 2022-07-28 I present the final draft of my professional valuation of Lockheed Martin Corporation Equity per Share. I spent some hours cleaning up the prose (mostly light editing). I checked the citations, added "C-5" to Lockheed's notable creations, and worked to tighten up the grammar. As always, subsequent readings will inevitably reveal typographical and grammatical errors, but in general, this report is complete. I welcome any suggestions or complaints. Feedback always helps me improve my writing and my analysis. (I will be transitioning to work on a write-up on Gilead Sciences starting next week. From time to time I like to brush up on my biochemistry, molecular biology, and Phase Trial Studies.) <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/2022-07-28lmt-mc-valuationreportdraft03-220728135603-45ba029d-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> 2022-07-28 I present the final draft of my professional valuation of Lockheed Martin Corporation Equity per Share. I spent some hours cleaning up the prose (mostly light editing). I checked the citations, added &quot;C-5&quot; to Lockheed&#39;s notable creations, and worked to tighten up the grammar. As always, subsequent readings will inevitably reveal typographical and grammatical errors, but in general, this report is complete. I welcome any suggestions or complaints. Feedback always helps me improve my writing and my analysis. (I will be transitioning to work on a write-up on Gilead Sciences starting next week. From time to time I like to brush up on my biochemistry, molecular biology, and Phase Trial Studies.)
2022-07-28_LMT-MC-ValuationReport_Draft03.pdf from Lyndon Martin W. Beharry
]]> 42 0 https://cdn.slidesharecdn.com/ss_thumbnails/2022-07-28lmt-mc-valuationreportdraft03-220728135603-45ba029d-thumbnail.jpg?width=120&height=120&fit=bounds document Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 2022-07-26_LMT-MC-ValuationReport_Draft02.pdf /slideshow/20220726lmtmcvaluationreportdraft02pdf/252338864 2022-07-26lmt-mc-valuationreportdraft02-220727192854-f42476c9
I present the second draft of my professional valuation of Lockheed Martin Corporation Equity per Share. I am satisfied with the variables, the cashflow projections, and the discounting; so this item does carry my estimate of LMT's present valuation. I worked on the History (p. 2) and the WACC calculations (did some Excel coding after I found a slight Drop down menu / VLookup error) and I finalized the recommendations pp. 6, 7, & 10. I hope my readers enjoy it as much as I am enjoying producing it!]]>
I present the second draft of my professional valuation of Lockheed Martin Corporation Equity per Share. I am satisfied with the variables, the cashflow projections, and the discounting; so this item does carry my estimate of LMT's present valuation. I worked on the History (p. 2) and the WACC calculations (did some Excel coding after I found a slight Drop down menu / VLookup error) and I finalized the recommendations pp. 6, 7, & 10. I hope my readers enjoy it as much as I am enjoying producing it!]]> Wed, 27 Jul 2022 19:28:53 GMT /slideshow/20220726lmtmcvaluationreportdraft02pdf/252338864 LMBeharry@slideshare.net(LMBeharry) 2022-07-26_LMT-MC-ValuationReport_Draft02.pdf LMBeharry I present the second draft of my professional valuation of Lockheed Martin Corporation Equity per Share. I am satisfied with the variables, the cashflow projections, and the discounting; so this item does carry my estimate of LMT's present valuation. I worked on the History (p. 2) and the WACC calculations (did some Excel coding after I found a slight Drop down menu / VLookup error) and I finalized the recommendations pp. 6, 7, & 10. I hope my readers enjoy it as much as I am enjoying producing it! <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/2022-07-26lmt-mc-valuationreportdraft02-220727192854-f42476c9-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> I present the second draft of my professional valuation of Lockheed Martin Corporation Equity per Share. I am satisfied with the variables, the cashflow projections, and the discounting; so this item does carry my estimate of LMT&#39;s present valuation. I worked on the History (p. 2) and the WACC calculations (did some Excel coding after I found a slight Drop down menu / VLookup error) and I finalized the recommendations pp. 6, 7, &amp; 10. I hope my readers enjoy it as much as I am enjoying producing it!
2022-07-26_LMT-MC-ValuationReport_Draft02.pdf from Lyndon Martin W. Beharry
]]> 49 0 https://cdn.slidesharecdn.com/ss_thumbnails/2022-07-26lmt-mc-valuationreportdraft02-220727192854-f42476c9-thumbnail.jpg?width=120&height=120&fit=bounds document Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 2022-07-26_LMT-MC-ValuationReport_Draft01.pdf /slideshow/20220726lmtmcvaluationreportdraft01pdf/252326221 2022-07-26lmt-mc-valuationreportdraft01-220726215624-82d9590f
I am eager to share this report on Lockheed's Monte Carlo Equity Valuation. I have been working on this write-up for Lockheed Martin and I think I am in striking range of completion, so I am sharing the first draft. I hope to round out the PESTLE and Porter Analysis this week and clean up the text, so look forward to a final draft during the first or second week of August.]]>
I am eager to share this report on Lockheed's Monte Carlo Equity Valuation. I have been working on this write-up for Lockheed Martin and I think I am in striking range of completion, so I am sharing the first draft. I hope to round out the PESTLE and Porter Analysis this week and clean up the text, so look forward to a final draft during the first or second week of August.]]> Tue, 26 Jul 2022 21:56:23 GMT /slideshow/20220726lmtmcvaluationreportdraft01pdf/252326221 LMBeharry@slideshare.net(LMBeharry) 2022-07-26_LMT-MC-ValuationReport_Draft01.pdf LMBeharry I am eager to share this report on Lockheed's Monte Carlo Equity Valuation. I have been working on this write-up for Lockheed Martin and I think I am in striking range of completion, so I am sharing the first draft. I hope to round out the PESTLE and Porter Analysis this week and clean up the text, so look forward to a final draft during the first or second week of August. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/2022-07-26lmt-mc-valuationreportdraft01-220726215624-82d9590f-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> I am eager to share this report on Lockheed&#39;s Monte Carlo Equity Valuation. I have been working on this write-up for Lockheed Martin and I think I am in striking range of completion, so I am sharing the first draft. I hope to round out the PESTLE and Porter Analysis this week and clean up the text, so look forward to a final draft during the first or second week of August.
2022-07-26_LMT-MC-ValuationReport_Draft01.pdf from Lyndon Martin W. Beharry
]]> 27 0 https://cdn.slidesharecdn.com/ss_thumbnails/2022-07-26lmt-mc-valuationreportdraft01-220726215624-82d9590f-thumbnail.jpg?width=120&height=120&fit=bounds document Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 2022-07-22_KHC_MC-Equity-1Million_July-Trials.pdf /slideshow/20220722khcmcequity1millionjulytrialspdf/252281976 2022-07-22khcmc-equity-1millionjuly-trials-220722201247-e34c30dc
This Monte Carlo multi-iteration DCF Model returns a fair value for Kraft Heinz: $35.496 . The static Model returns a valuation of $34.388 . These models are conservative estimates projecting zero growth forward using cost factors pulled from the mean of the prior 15 years with a coefficient of variability of the cost factors equal to 10%. Kraft Heinz Company pays a dividend yield of 4.20% ay July 22, 2022. KHC: Kraft Heinz Company came up on the screen I had completed earlier in the week on Tuesday, and it has been one of my favorites for many years (from before the divestiture of certain assets to Mondelez. Kraft is a textbook example of a stable U.S. entity which made a successful transition to multinational operations through purposefully introducing itself to various foreign markets, and also through astute trades and/or investments into food companies abroad. Kraft has significant presence in Europe, Asia, and Latin America; and a growing presence in Africa. The Kraft Heinz Company, together with its subsidiaries, manufactures and markets food and beverage products in the United States, Canada, the United Kingdom, and internationally. Its products include condiments and sauces, cheese and dairy products, meals, meats, refreshment beverages, coffee, and other grocery products. The company also offers dressings, healthy snacks, and other categories; and spices and other seasonings. It sells its products through its own sales organizations, as well as through independent brokers, agents, and distributors to chain, wholesale, cooperative and independent grocery accounts, convenience stores, drug stores, value stores, bakeries, pharmacies, mass merchants, club stores, and foodservice distributors and institutions, including hotels, restaurants, hospitals, health care facilities, and government agencies; and online through various e-commerce platforms and retailers. The company was formerly known as H.J. Heinz Holding Corporation and changed its name to The Kraft Heinz Company in July 2015. The Kraft Heinz Company was founded in 1869 and is headquartered in Pittsburgh, Pennsylvania. (FY: 2021-12-25)]]>
This Monte Carlo multi-iteration DCF Model returns a fair value for Kraft Heinz: $35.496 . The static Model returns a valuation of $34.388 . These models are conservative estimates projecting zero growth forward using cost factors pulled from the mean of the prior 15 years with a coefficient of variability of the cost factors equal to 10%. Kraft Heinz Company pays a dividend yield of 4.20% ay July 22, 2022. KHC: Kraft Heinz Company came up on the screen I had completed earlier in the week on Tuesday, and it has been one of my favorites for many years (from before the divestiture of certain assets to Mondelez. Kraft is a textbook example of a stable U.S. entity which made a successful transition to multinational operations through purposefully introducing itself to various foreign markets, and also through astute trades and/or investments into food companies abroad. Kraft has significant presence in Europe, Asia, and Latin America; and a growing presence in Africa. The Kraft Heinz Company, together with its subsidiaries, manufactures and markets food and beverage products in the United States, Canada, the United Kingdom, and internationally. Its products include condiments and sauces, cheese and dairy products, meals, meats, refreshment beverages, coffee, and other grocery products. The company also offers dressings, healthy snacks, and other categories; and spices and other seasonings. It sells its products through its own sales organizations, as well as through independent brokers, agents, and distributors to chain, wholesale, cooperative and independent grocery accounts, convenience stores, drug stores, value stores, bakeries, pharmacies, mass merchants, club stores, and foodservice distributors and institutions, including hotels, restaurants, hospitals, health care facilities, and government agencies; and online through various e-commerce platforms and retailers. The company was formerly known as H.J. Heinz Holding Corporation and changed its name to The Kraft Heinz Company in July 2015. The Kraft Heinz Company was founded in 1869 and is headquartered in Pittsburgh, Pennsylvania. (FY: 2021-12-25)]]> Fri, 22 Jul 2022 20:12:46 GMT /slideshow/20220722khcmcequity1millionjulytrialspdf/252281976 LMBeharry@slideshare.net(LMBeharry) 2022-07-22_KHC_MC-Equity-1Million_July-Trials.pdf LMBeharry This Monte Carlo multi-iteration DCF Model returns a fair value for Kraft Heinz: $35.496 . The static Model returns a valuation of $34.388 . These models are conservative estimates projecting zero growth forward using cost factors pulled from the mean of the prior 15 years with a coefficient of variability of the cost factors equal to 10%. Kraft Heinz Company pays a dividend yield of 4.20% ay July 22, 2022. KHC: Kraft Heinz Company came up on the screen I had completed earlier in the week on Tuesday, and it has been one of my favorites for many years (from before the divestiture of certain assets to Mondelez. Kraft is a textbook example of a stable U.S. entity which made a successful transition to multinational operations through purposefully introducing itself to various foreign markets, and also through astute trades and/or investments into food companies abroad. Kraft has significant presence in Europe, Asia, and Latin America; and a growing presence in Africa. The Kraft Heinz Company, together with its subsidiaries, manufactures and markets food and beverage products in the United States, Canada, the United Kingdom, and internationally. Its products include condiments and sauces, cheese and dairy products, meals, meats, refreshment beverages, coffee, and other grocery products. The company also offers dressings, healthy snacks, and other categories; and spices and other seasonings. It sells its products through its own sales organizations, as well as through independent brokers, agents, and distributors to chain, wholesale, cooperative and independent grocery accounts, convenience stores, drug stores, value stores, bakeries, pharmacies, mass merchants, club stores, and foodservice distributors and institutions, including hotels, restaurants, hospitals, health care facilities, and government agencies; and online through various e-commerce platforms and retailers. The company was formerly known as H.J. Heinz Holding Corporation and changed its name to The Kraft Heinz Company in July 2015. The Kraft Heinz Company was founded in 1869 and is headquartered in Pittsburgh, Pennsylvania. (FY: 2021-12-25) <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/2022-07-22khcmc-equity-1millionjuly-trials-220722201247-e34c30dc-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> This Monte Carlo multi-iteration DCF Model returns a fair value for Kraft Heinz: $35.496 . The static Model returns a valuation of $34.388 . These models are conservative estimates projecting zero growth forward using cost factors pulled from the mean of the prior 15 years with a coefficient of variability of the cost factors equal to 10%. Kraft Heinz Company pays a dividend yield of 4.20% ay July 22, 2022. KHC: Kraft Heinz Company came up on the screen I had completed earlier in the week on Tuesday, and it has been one of my favorites for many years (from before the divestiture of certain assets to Mondelez. Kraft is a textbook example of a stable U.S. entity which made a successful transition to multinational operations through purposefully introducing itself to various foreign markets, and also through astute trades and/or investments into food companies abroad. Kraft has significant presence in Europe, Asia, and Latin America; and a growing presence in Africa. The Kraft Heinz Company, together with its subsidiaries, manufactures and markets food and beverage products in the United States, Canada, the United Kingdom, and internationally. Its products include condiments and sauces, cheese and dairy products, meals, meats, refreshment beverages, coffee, and other grocery products. The company also offers dressings, healthy snacks, and other categories; and spices and other seasonings. It sells its products through its own sales organizations, as well as through independent brokers, agents, and distributors to chain, wholesale, cooperative and independent grocery accounts, convenience stores, drug stores, value stores, bakeries, pharmacies, mass merchants, club stores, and foodservice distributors and institutions, including hotels, restaurants, hospitals, health care facilities, and government agencies; and online through various e-commerce platforms and retailers. The company was formerly known as H.J. Heinz Holding Corporation and changed its name to The Kraft Heinz Company in July 2015. The Kraft Heinz Company was founded in 1869 and is headquartered in Pittsburgh, Pennsylvania. (FY: 2021-12-25)
2022-07-22_KHC_MC-Equity-1Million_July-Trials.pdf from Lyndon Martin W. Beharry
]]> 8 0 https://cdn.slidesharecdn.com/ss_thumbnails/2022-07-22khcmc-equity-1millionjuly-trials-220722201247-e34c30dc-thumbnail.jpg?width=120&height=120&fit=bounds document Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 2022-07-20_GILD_MC-Equity-1Million_July-Trials.pdf /slideshow/20220720gildmcequity1millionjulytrialspdf/252254705 2022-07-20gildmc-equity-1millionjuly-trials-220720175623-3cd66c65
GILD 2021 10K: Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades. In 2021, the firm's primary revenue drivers originate with medications designed to combat HIV, AIDs and its symptoms. Gilead has also produced medications for combatting coronavirus disease 2019 (COVID-19). The firm also researches and manufactures medications treating liver disease. The firm serves the international market and has a vibrant and active pipeline of R&D, and potential offerings in various stages of testing and/or awaiting regulatory approval. (FY: 2021-12-31) These Monte Carlo DCF and Static DCF analyses hold revenue growth to 0.00% (no growth) while modeling the income statement cost components following 15-year historic means and a coefficient of variability of 10%. (Many analysts are forecasting retracting revenue of between 1.0% and 2.5% for the foreseeable years.) Even at no growth of revenue, Monte Carlo analysis returns excellent and stable valuations for Gilead with a lower bound of approximately $43.70 and an upper bound of about $96.80 . In addition Gilead pays a healthy dividend yielding 4.66% at its current trading price of $66. This analyst will expend some additional effort reviewing the firm's Phase Trial Clinical studies and pipeline for FDA and/or EU approval. Those qualitative reports will follow in the coming month.]]>
GILD 2021 10K: Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades. In 2021, the firm's primary revenue drivers originate with medications designed to combat HIV, AIDs and its symptoms. Gilead has also produced medications for combatting coronavirus disease 2019 (COVID-19). The firm also researches and manufactures medications treating liver disease. The firm serves the international market and has a vibrant and active pipeline of R&D, and potential offerings in various stages of testing and/or awaiting regulatory approval. (FY: 2021-12-31) These Monte Carlo DCF and Static DCF analyses hold revenue growth to 0.00% (no growth) while modeling the income statement cost components following 15-year historic means and a coefficient of variability of 10%. (Many analysts are forecasting retracting revenue of between 1.0% and 2.5% for the foreseeable years.) Even at no growth of revenue, Monte Carlo analysis returns excellent and stable valuations for Gilead with a lower bound of approximately $43.70 and an upper bound of about $96.80 . In addition Gilead pays a healthy dividend yielding 4.66% at its current trading price of $66. This analyst will expend some additional effort reviewing the firm's Phase Trial Clinical studies and pipeline for FDA and/or EU approval. Those qualitative reports will follow in the coming month.]]> Wed, 20 Jul 2022 17:56:23 GMT /slideshow/20220720gildmcequity1millionjulytrialspdf/252254705 LMBeharry@slideshare.net(LMBeharry) 2022-07-20_GILD_MC-Equity-1Million_July-Trials.pdf LMBeharry GILD 2021 10K: Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades. In 2021, the firm's primary revenue drivers originate with medications designed to combat HIV, AIDs and its symptoms. Gilead has also produced medications for combatting coronavirus disease 2019 (COVID-19). The firm also researches and manufactures medications treating liver disease. The firm serves the international market and has a vibrant and active pipeline of R&D, and potential offerings in various stages of testing and/or awaiting regulatory approval. (FY: 2021-12-31) These Monte Carlo DCF and Static DCF analyses hold revenue growth to 0.00% (no growth) while modeling the income statement cost components following 15-year historic means and a coefficient of variability of 10%. (Many analysts are forecasting retracting revenue of between 1.0% and 2.5% for the foreseeable years.) Even at no growth of revenue, Monte Carlo analysis returns excellent and stable valuations for Gilead with a lower bound of approximately $43.70 and an upper bound of about $96.80 . In addition Gilead pays a healthy dividend yielding 4.66% at its current trading price of $66. This analyst will expend some additional effort reviewing the firm's Phase Trial Clinical studies and pipeline for FDA and/or EU approval. Those qualitative reports will follow in the coming month. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/2022-07-20gildmc-equity-1millionjuly-trials-220720175623-3cd66c65-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> GILD 2021 10K: Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades. In 2021, the firm&#39;s primary revenue drivers originate with medications designed to combat HIV, AIDs and its symptoms. Gilead has also produced medications for combatting coronavirus disease 2019 (COVID-19). The firm also researches and manufactures medications treating liver disease. The firm serves the international market and has a vibrant and active pipeline of R&amp;D, and potential offerings in various stages of testing and/or awaiting regulatory approval. (FY: 2021-12-31) These Monte Carlo DCF and Static DCF analyses hold revenue growth to 0.00% (no growth) while modeling the income statement cost components following 15-year historic means and a coefficient of variability of 10%. (Many analysts are forecasting retracting revenue of between 1.0% and 2.5% for the foreseeable years.) Even at no growth of revenue, Monte Carlo analysis returns excellent and stable valuations for Gilead with a lower bound of approximately $43.70 and an upper bound of about $96.80 . In addition Gilead pays a healthy dividend yielding 4.66% at its current trading price of $66. This analyst will expend some additional effort reviewing the firm&#39;s Phase Trial Clinical studies and pipeline for FDA and/or EU approval. Those qualitative reports will follow in the coming month.
2022-07-20_GILD_MC-Equity-1Million_July-Trials.pdf from Lyndon Martin W. Beharry
]]> 7 0 https://cdn.slidesharecdn.com/ss_thumbnails/2022-07-20gildmc-equity-1millionjuly-trials-220720175623-3cd66c65-thumbnail.jpg?width=120&height=120&fit=bounds document Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 2022-07-19_BBBY_MC-Equity-1Million_July-Trials-SWOT.pdf /slideshow/20220719bbbymcequity1millionjulytrialsswotpdf/252240083 2022-07-19bbbymc-equity-1millionjuly-trials-swot-220719171314-e19ef0bd
I spent the morning updating BBBY: Bed Bath and Beyond. Crazy SGA volatility coupled with Covid quarantines to cripple this long-time Brick & Mortar household goods brand. The firm has some culture *problems*. Notably, stores were traditionally free to run themselves, carrying product lines local management surmised the local community cherished. Hence, there were never any true scale economies in purchasing inventory. Other problems include over-reliance on brick and mortar stores to the detriment of internet marketing; an *early/long-time* history of coupons which never expired; *early/long-time* history of "free" shipping; and other things. On the plus side, BBBY owns much of its real property and has long-term leases on other holdings. These valuable items are still booked at acquisition costs (c. 1970s-80s real property values) and would generate substantial returns if the firm would transition to a more robust online presence and lease out much of its brick and mortar network. Only time will tell; if, that is, the firm is able to weather the next likely terrible 24 months of horrendous sales... Monte Carlo DCF projections reflect HUGE volatility. At 0.00% revenue growth, the model returns a range of valuation from a low of -$260.02 (yes, that is a negative number) and up to a maximum of +$256. I had reviewed BBBY way back in 2019, and I think that SWOT analysis is still useful, so I tacked it onto this quantitative analytical summary. Bed Bath & Beyond Inc., together with its subsidiaries, operates a chain of retail stores. It sells a range of domestics merchandise, including bed linens and related items, bath items, and kitchen textiles; and home furnishings, such as kitchen and tabletop items, fine tabletop, basic housewares, general home furnishings, consumables, and various juvenile products. As of February 26, 2022, the company had 953 stores, which included 771 Bed Bath & Beyond stores in 50 states, the District of Columbia, Puerto Rico, and Canada; 130 buybuy BABY stores in 37 states and Canada; and 52 stores in 6 states under the names Harmon, Harmon Face Values or Face Values. It also offers products through various Websites and applications comprising bedbathandbeyond.com, bedbathandbeyond.ca, harmondiscount.com, facevalues.com, buybuybaby.com, buybuybaby.ca, and decorist.com. In addition, the company operates Decorist, an online interior design platform that provides personalized home design services. Bed Bath & Beyond Inc. was incorporated in 1971 and is headquartered in Union, New Jersey.]]>
I spent the morning updating BBBY: Bed Bath and Beyond. Crazy SGA volatility coupled with Covid quarantines to cripple this long-time Brick & Mortar household goods brand. The firm has some culture *problems*. Notably, stores were traditionally free to run themselves, carrying product lines local management surmised the local community cherished. Hence, there were never any true scale economies in purchasing inventory. Other problems include over-reliance on brick and mortar stores to the detriment of internet marketing; an *early/long-time* history of coupons which never expired; *early/long-time* history of "free" shipping; and other things. On the plus side, BBBY owns much of its real property and has long-term leases on other holdings. These valuable items are still booked at acquisition costs (c. 1970s-80s real property values) and would generate substantial returns if the firm would transition to a more robust online presence and lease out much of its brick and mortar network. Only time will tell; if, that is, the firm is able to weather the next likely terrible 24 months of horrendous sales... Monte Carlo DCF projections reflect HUGE volatility. At 0.00% revenue growth, the model returns a range of valuation from a low of -$260.02 (yes, that is a negative number) and up to a maximum of +$256. I had reviewed BBBY way back in 2019, and I think that SWOT analysis is still useful, so I tacked it onto this quantitative analytical summary. Bed Bath & Beyond Inc., together with its subsidiaries, operates a chain of retail stores. It sells a range of domestics merchandise, including bed linens and related items, bath items, and kitchen textiles; and home furnishings, such as kitchen and tabletop items, fine tabletop, basic housewares, general home furnishings, consumables, and various juvenile products. As of February 26, 2022, the company had 953 stores, which included 771 Bed Bath & Beyond stores in 50 states, the District of Columbia, Puerto Rico, and Canada; 130 buybuy BABY stores in 37 states and Canada; and 52 stores in 6 states under the names Harmon, Harmon Face Values or Face Values. It also offers products through various Websites and applications comprising bedbathandbeyond.com, bedbathandbeyond.ca, harmondiscount.com, facevalues.com, buybuybaby.com, buybuybaby.ca, and decorist.com. In addition, the company operates Decorist, an online interior design platform that provides personalized home design services. Bed Bath & Beyond Inc. was incorporated in 1971 and is headquartered in Union, New Jersey.]]> Tue, 19 Jul 2022 17:13:14 GMT /slideshow/20220719bbbymcequity1millionjulytrialsswotpdf/252240083 LMBeharry@slideshare.net(LMBeharry) 2022-07-19_BBBY_MC-Equity-1Million_July-Trials-SWOT.pdf LMBeharry I spent the morning updating BBBY: Bed Bath and Beyond. Crazy SGA volatility coupled with Covid quarantines to cripple this long-time Brick & Mortar household goods brand. The firm has some culture *problems*. Notably, stores were traditionally free to run themselves, carrying product lines local management surmised the local community cherished. Hence, there were never any true scale economies in purchasing inventory. Other problems include over-reliance on brick and mortar stores to the detriment of internet marketing; an *early/long-time* history of coupons which never expired; *early/long-time* history of "free" shipping; and other things. On the plus side, BBBY owns much of its real property and has long-term leases on other holdings. These valuable items are still booked at acquisition costs (c. 1970s-80s real property values) and would generate substantial returns if the firm would transition to a more robust online presence and lease out much of its brick and mortar network. Only time will tell; if, that is, the firm is able to weather the next likely terrible 24 months of horrendous sales... Monte Carlo DCF projections reflect HUGE volatility. At 0.00% revenue growth, the model returns a range of valuation from a low of -$260.02 (yes, that is a negative number) and up to a maximum of +$256. I had reviewed BBBY way back in 2019, and I think that SWOT analysis is still useful, so I tacked it onto this quantitative analytical summary. Bed Bath & Beyond Inc., together with its subsidiaries, operates a chain of retail stores. It sells a range of domestics merchandise, including bed linens and related items, bath items, and kitchen textiles; and home furnishings, such as kitchen and tabletop items, fine tabletop, basic housewares, general home furnishings, consumables, and various juvenile products. As of February 26, 2022, the company had 953 stores, which included 771 Bed Bath & Beyond stores in 50 states, the District of Columbia, Puerto Rico, and Canada; 130 buybuy BABY stores in 37 states and Canada; and 52 stores in 6 states under the names Harmon, Harmon Face Values or Face Values. It also offers products through various Websites and applications comprising bedbathandbeyond.com, bedbathandbeyond.ca, harmondiscount.com, facevalues.com, buybuybaby.com, buybuybaby.ca, and decorist.com. In addition, the company operates Decorist, an online interior design platform that provides personalized home design services. Bed Bath & Beyond Inc. was incorporated in 1971 and is headquartered in Union, New Jersey. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/2022-07-19bbbymc-equity-1millionjuly-trials-swot-220719171314-e19ef0bd-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> I spent the morning updating BBBY: Bed Bath and Beyond. Crazy SGA volatility coupled with Covid quarantines to cripple this long-time Brick &amp; Mortar household goods brand. The firm has some culture *problems*. Notably, stores were traditionally free to run themselves, carrying product lines local management surmised the local community cherished. Hence, there were never any true scale economies in purchasing inventory. Other problems include over-reliance on brick and mortar stores to the detriment of internet marketing; an *early/long-time* history of coupons which never expired; *early/long-time* history of &quot;free&quot; shipping; and other things. On the plus side, BBBY owns much of its real property and has long-term leases on other holdings. These valuable items are still booked at acquisition costs (c. 1970s-80s real property values) and would generate substantial returns if the firm would transition to a more robust online presence and lease out much of its brick and mortar network. Only time will tell; if, that is, the firm is able to weather the next likely terrible 24 months of horrendous sales... Monte Carlo DCF projections reflect HUGE volatility. At 0.00% revenue growth, the model returns a range of valuation from a low of -$260.02 (yes, that is a negative number) and up to a maximum of +$256. I had reviewed BBBY way back in 2019, and I think that SWOT analysis is still useful, so I tacked it onto this quantitative analytical summary. Bed Bath &amp; Beyond Inc., together with its subsidiaries, operates a chain of retail stores. It sells a range of domestics merchandise, including bed linens and related items, bath items, and kitchen textiles; and home furnishings, such as kitchen and tabletop items, fine tabletop, basic housewares, general home furnishings, consumables, and various juvenile products. As of February 26, 2022, the company had 953 stores, which included 771 Bed Bath &amp; Beyond stores in 50 states, the District of Columbia, Puerto Rico, and Canada; 130 buybuy BABY stores in 37 states and Canada; and 52 stores in 6 states under the names Harmon, Harmon Face Values or Face Values. It also offers products through various Websites and applications comprising bedbathandbeyond.com, bedbathandbeyond.ca, harmondiscount.com, facevalues.com, buybuybaby.com, buybuybaby.ca, and decorist.com. In addition, the company operates Decorist, an online interior design platform that provides personalized home design services. Bed Bath &amp; Beyond Inc. was incorporated in 1971 and is headquartered in Union, New Jersey.
2022-07-19_BBBY_MC-Equity-1Million_July-Trials-SWOT.pdf from Lyndon Martin W. Beharry
]]> 23 0 https://cdn.slidesharecdn.com/ss_thumbnails/2022-07-19bbbymc-equity-1millionjuly-trials-swot-220719171314-e19ef0bd-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 2022-07-18_DVN_MC-Equity-1Million_July-Trials.pdf /LMBeharry/20220718dvnmcequity1millionjulytrialspdf 2022-07-18dvnmc-equity-1millionjuly-trials-220718161607-5b155a4f
Post 2000s, Oil and Gas company valuations are particularly problematic. On the one hand, they still service the bulk of humanity's energy demands. In fact, it is oil, gas, shale, and coal which provide the bulk of the energy used to manufacture Green Energy infrastructure (turbines, solar, hydro, and even geo-thermal) - and fossil fuels will continue to dominate the energy produced for the manufacture of Green Energy technology for decades to come. But on the other hand, we all know that humanity must move away from fossil fuels and Developed World nation-states all have varying degrees of regulations requiring phasing out fossil fuel use and technology within this century. Less Developed Countries (LDCs) are beginning to leap-frog, totally bypassing fossil fuel energy infrastructure and directly embracing Green Energy production (infrastructure constructed in Developed World and BRIC (mainly China) using fossil fuel energy). Furthermore, shale oil (fracking) has empowered U.S. and Canada with enough surplus to become net exporters of oil, and this plays havoc with world oil pricing (notwithstanding the current situation of high prices with the ongoing war in Ukraine). So ... revenue growth rates, Capital Expenditures, even Depreciation Schedules all become difficult to model. This analysis uses a modest forward 12.50% revenue growth rate (normal distribution; coefficient of variability 10%), with cost structure parameters taking the mean of 15-Yr historic patterns (high standard deviations, though); and a U.S. tax loading of 17% accommodating U.S. federal subsidies and favoritism to American Petroleum Institute lobby. Bear in mind, though, that the Revenue Growth rate could go negative on a dime, as it had done in the 2010s, when oil and gas retracted and spent next to nothing on Capital Expenditure and discovery. So, yeah. Fossil Fuel producers: oil and gas (not so much coal) are very difficult to value in this climate. These variables produce a low range of potential value for Devon Energy Corporation. The obvious workaround would be to broaden the coefficient of variability for the Revenue growth rate and cost parameters. But this option is not attractive because, while more accurately mimicking true-to-life historical volatility in asset pricing, it would produce too broad a range of scenario valuation as to be of any practical use. So this instant valuation produces a rather low valuation estimate, indeed.]]>
Post 2000s, Oil and Gas company valuations are particularly problematic. On the one hand, they still service the bulk of humanity's energy demands. In fact, it is oil, gas, shale, and coal which provide the bulk of the energy used to manufacture Green Energy infrastructure (turbines, solar, hydro, and even geo-thermal) - and fossil fuels will continue to dominate the energy produced for the manufacture of Green Energy technology for decades to come. But on the other hand, we all know that humanity must move away from fossil fuels and Developed World nation-states all have varying degrees of regulations requiring phasing out fossil fuel use and technology within this century. Less Developed Countries (LDCs) are beginning to leap-frog, totally bypassing fossil fuel energy infrastructure and directly embracing Green Energy production (infrastructure constructed in Developed World and BRIC (mainly China) using fossil fuel energy). Furthermore, shale oil (fracking) has empowered U.S. and Canada with enough surplus to become net exporters of oil, and this plays havoc with world oil pricing (notwithstanding the current situation of high prices with the ongoing war in Ukraine). So ... revenue growth rates, Capital Expenditures, even Depreciation Schedules all become difficult to model. This analysis uses a modest forward 12.50% revenue growth rate (normal distribution; coefficient of variability 10%), with cost structure parameters taking the mean of 15-Yr historic patterns (high standard deviations, though); and a U.S. tax loading of 17% accommodating U.S. federal subsidies and favoritism to American Petroleum Institute lobby. Bear in mind, though, that the Revenue Growth rate could go negative on a dime, as it had done in the 2010s, when oil and gas retracted and spent next to nothing on Capital Expenditure and discovery. So, yeah. Fossil Fuel producers: oil and gas (not so much coal) are very difficult to value in this climate. These variables produce a low range of potential value for Devon Energy Corporation. The obvious workaround would be to broaden the coefficient of variability for the Revenue growth rate and cost parameters. But this option is not attractive because, while more accurately mimicking true-to-life historical volatility in asset pricing, it would produce too broad a range of scenario valuation as to be of any practical use. So this instant valuation produces a rather low valuation estimate, indeed.]]> Mon, 18 Jul 2022 16:16:07 GMT /LMBeharry/20220718dvnmcequity1millionjulytrialspdf LMBeharry@slideshare.net(LMBeharry) 2022-07-18_DVN_MC-Equity-1Million_July-Trials.pdf LMBeharry Post 2000s, Oil and Gas company valuations are particularly problematic. On the one hand, they still service the bulk of humanity's energy demands. In fact, it is oil, gas, shale, and coal which provide the bulk of the energy used to manufacture Green Energy infrastructure (turbines, solar, hydro, and even geo-thermal) - and fossil fuels will continue to dominate the energy produced for the manufacture of Green Energy technology for decades to come. But on the other hand, we all know that humanity must move away from fossil fuels and Developed World nation-states all have varying degrees of regulations requiring phasing out fossil fuel use and technology within this century. Less Developed Countries (LDCs) are beginning to leap-frog, totally bypassing fossil fuel energy infrastructure and directly embracing Green Energy production (infrastructure constructed in Developed World and BRIC (mainly China) using fossil fuel energy). Furthermore, shale oil (fracking) has empowered U.S. and Canada with enough surplus to become net exporters of oil, and this plays havoc with world oil pricing (notwithstanding the current situation of high prices with the ongoing war in Ukraine). So ... revenue growth rates, Capital Expenditures, even Depreciation Schedules all become difficult to model. This analysis uses a modest forward 12.50% revenue growth rate (normal distribution; coefficient of variability 10%), with cost structure parameters taking the mean of 15-Yr historic patterns (high standard deviations, though); and a U.S. tax loading of 17% accommodating U.S. federal subsidies and favoritism to American Petroleum Institute lobby. Bear in mind, though, that the Revenue Growth rate could go negative on a dime, as it had done in the 2010s, when oil and gas retracted and spent next to nothing on Capital Expenditure and discovery. So, yeah. Fossil Fuel producers: oil and gas (not so much coal) are very difficult to value in this climate. These variables produce a low range of potential value for Devon Energy Corporation. The obvious workaround would be to broaden the coefficient of variability for the Revenue growth rate and cost parameters. But this option is not attractive because, while more accurately mimicking true-to-life historical volatility in asset pricing, it would produce too broad a range of scenario valuation as to be of any practical use. So this instant valuation produces a rather low valuation estimate, indeed. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/2022-07-18dvnmc-equity-1millionjuly-trials-220718161607-5b155a4f-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> Post 2000s, Oil and Gas company valuations are particularly problematic. On the one hand, they still service the bulk of humanity&#39;s energy demands. In fact, it is oil, gas, shale, and coal which provide the bulk of the energy used to manufacture Green Energy infrastructure (turbines, solar, hydro, and even geo-thermal) - and fossil fuels will continue to dominate the energy produced for the manufacture of Green Energy technology for decades to come. But on the other hand, we all know that humanity must move away from fossil fuels and Developed World nation-states all have varying degrees of regulations requiring phasing out fossil fuel use and technology within this century. Less Developed Countries (LDCs) are beginning to leap-frog, totally bypassing fossil fuel energy infrastructure and directly embracing Green Energy production (infrastructure constructed in Developed World and BRIC (mainly China) using fossil fuel energy). Furthermore, shale oil (fracking) has empowered U.S. and Canada with enough surplus to become net exporters of oil, and this plays havoc with world oil pricing (notwithstanding the current situation of high prices with the ongoing war in Ukraine). So ... revenue growth rates, Capital Expenditures, even Depreciation Schedules all become difficult to model. This analysis uses a modest forward 12.50% revenue growth rate (normal distribution; coefficient of variability 10%), with cost structure parameters taking the mean of 15-Yr historic patterns (high standard deviations, though); and a U.S. tax loading of 17% accommodating U.S. federal subsidies and favoritism to American Petroleum Institute lobby. Bear in mind, though, that the Revenue Growth rate could go negative on a dime, as it had done in the 2010s, when oil and gas retracted and spent next to nothing on Capital Expenditure and discovery. So, yeah. Fossil Fuel producers: oil and gas (not so much coal) are very difficult to value in this climate. These variables produce a low range of potential value for Devon Energy Corporation. The obvious workaround would be to broaden the coefficient of variability for the Revenue growth rate and cost parameters. But this option is not attractive because, while more accurately mimicking true-to-life historical volatility in asset pricing, it would produce too broad a range of scenario valuation as to be of any practical use. So this instant valuation produces a rather low valuation estimate, indeed.
2022-07-18_DVN_MC-Equity-1Million_July-Trials.pdf from Lyndon Martin W. Beharry
]]> 12 0 https://cdn.slidesharecdn.com/ss_thumbnails/2022-07-18dvnmc-equity-1millionjuly-trials-220718161607-5b155a4f-thumbnail.jpg?width=120&height=120&fit=bounds document Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 2022-07-16_MMM_MC-Equity-1Million_July-Trials.pdf /slideshow/20220716mmmmcequity1millionjulytrialspdf/252205853 2022-07-16mmmmc-equity-1millionjuly-trials-220716204835-9a3923d7
3M is interesting. It is a multinational conglomerate with production and sales ranging from household goods to medical devices. The numerical analysis is straightforward. But the trick AND the excitement of valuing these types of companies is that it forces the analyst to learn about the various production methods and markets for disparate ranges of products and look at the company as a true portfolio of cash-generating assets - the various productions - while analyzing and rating the risks of all of those different markets. I first looked at 3M back in 2016, and then - apparently I have never looked at it since, because the Excel file in my Equity Valuation folders has not been revised in five or six years. Well, it got some treatment today. This is an econometrics analysis of quantitative data for 3M. I will review some qualitative data in the coming weeks, but based on the numbers, it looks really good. I included 10 iterations of the 1 Million steps to the Monte Carlo DCF. Enjoy.]]>
3M is interesting. It is a multinational conglomerate with production and sales ranging from household goods to medical devices. The numerical analysis is straightforward. But the trick AND the excitement of valuing these types of companies is that it forces the analyst to learn about the various production methods and markets for disparate ranges of products and look at the company as a true portfolio of cash-generating assets - the various productions - while analyzing and rating the risks of all of those different markets. I first looked at 3M back in 2016, and then - apparently I have never looked at it since, because the Excel file in my Equity Valuation folders has not been revised in five or six years. Well, it got some treatment today. This is an econometrics analysis of quantitative data for 3M. I will review some qualitative data in the coming weeks, but based on the numbers, it looks really good. I included 10 iterations of the 1 Million steps to the Monte Carlo DCF. Enjoy.]]> Sat, 16 Jul 2022 20:48:35 GMT /slideshow/20220716mmmmcequity1millionjulytrialspdf/252205853 LMBeharry@slideshare.net(LMBeharry) 2022-07-16_MMM_MC-Equity-1Million_July-Trials.pdf LMBeharry 3M is interesting. It is a multinational conglomerate with production and sales ranging from household goods to medical devices. The numerical analysis is straightforward. But the trick AND the excitement of valuing these types of companies is that it forces the analyst to learn about the various production methods and markets for disparate ranges of products and look at the company as a true portfolio of cash-generating assets - the various productions - while analyzing and rating the risks of all of those different markets. I first looked at 3M back in 2016, and then - apparently I have never looked at it since, because the Excel file in my Equity Valuation folders has not been revised in five or six years. Well, it got some treatment today. This is an econometrics analysis of quantitative data for 3M. I will review some qualitative data in the coming weeks, but based on the numbers, it looks really good. I included 10 iterations of the 1 Million steps to the Monte Carlo DCF. Enjoy. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/2022-07-16mmmmc-equity-1millionjuly-trials-220716204835-9a3923d7-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> 3M is interesting. It is a multinational conglomerate with production and sales ranging from household goods to medical devices. The numerical analysis is straightforward. But the trick AND the excitement of valuing these types of companies is that it forces the analyst to learn about the various production methods and markets for disparate ranges of products and look at the company as a true portfolio of cash-generating assets - the various productions - while analyzing and rating the risks of all of those different markets. I first looked at 3M back in 2016, and then - apparently I have never looked at it since, because the Excel file in my Equity Valuation folders has not been revised in five or six years. Well, it got some treatment today. This is an econometrics analysis of quantitative data for 3M. I will review some qualitative data in the coming weeks, but based on the numbers, it looks really good. I included 10 iterations of the 1 Million steps to the Monte Carlo DCF. Enjoy.
2022-07-16_MMM_MC-Equity-1Million_July-Trials.pdf from Lyndon Martin W. Beharry
]]> 25 0 https://cdn.slidesharecdn.com/ss_thumbnails/2022-07-16mmmmc-equity-1millionjuly-trials-220716204835-9a3923d7-thumbnail.jpg?width=120&height=120&fit=bounds document Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 2022-07-15_BIIB_MC-Equity-July-Trials.pdf /slideshow/20220715biibmcequityjulytrialspdf/252198344 2022-07-15biibmc-equity-july-trials-220715234449-a537ec54
I valued Biogen back in 2014 for an old friend, and I have looked in on it sporadically over the years. I did not like it back in the 2010s because it had too many competing therapies for multiple schlerosis (from my 2014 report here /LMBeharry/biib-reportlmbenterprises-59573190): " Several of the product offerings address multiple sclerosis, and these pharma products will likely begin cannibalizing each other within the intermediate term. The analyst believes that this cannibalization will curtail growth within the MS product line within the next 18 to 24 months." and " The firm has submitted hemophilia agents, Factor VIII and Factor IX to the US FDA for regulatory review, anticipating marketing approval in 2014-2015. As these hemophilia products are administered orally, analysts expect sales to grow robustly indeed. (i.e. more doctors will prescribe the treatment as it circumvents costly and frequent recurrent need of infusion of clotting factor). Statistics indicate that roughly 20,000 US residents suffer with hemophilia. A market of 20,000 patients is not a growth sector." Note that I have not kept up with its pipeline, nor its successes/failures at clinical trial. This printout is solely an exercise in econometric analysis using its historical cost structure to derive an equity valuation. If you are curious about its current research endeavors, I provide the link for clinical trials here (already sorted for Biogen): https://clinicaltrials.gov/ct2/results?cond=&term=Biogen&cntry=&state=&city=&dist=]]>
I valued Biogen back in 2014 for an old friend, and I have looked in on it sporadically over the years. I did not like it back in the 2010s because it had too many competing therapies for multiple schlerosis (from my 2014 report here /LMBeharry/biib-reportlmbenterprises-59573190): " Several of the product offerings address multiple sclerosis, and these pharma products will likely begin cannibalizing each other within the intermediate term. The analyst believes that this cannibalization will curtail growth within the MS product line within the next 18 to 24 months." and " The firm has submitted hemophilia agents, Factor VIII and Factor IX to the US FDA for regulatory review, anticipating marketing approval in 2014-2015. As these hemophilia products are administered orally, analysts expect sales to grow robustly indeed. (i.e. more doctors will prescribe the treatment as it circumvents costly and frequent recurrent need of infusion of clotting factor). Statistics indicate that roughly 20,000 US residents suffer with hemophilia. A market of 20,000 patients is not a growth sector." Note that I have not kept up with its pipeline, nor its successes/failures at clinical trial. This printout is solely an exercise in econometric analysis using its historical cost structure to derive an equity valuation. If you are curious about its current research endeavors, I provide the link for clinical trials here (already sorted for Biogen): https://clinicaltrials.gov/ct2/results?cond=&term=Biogen&cntry=&state=&city=&dist=]]> Fri, 15 Jul 2022 23:44:49 GMT /slideshow/20220715biibmcequityjulytrialspdf/252198344 LMBeharry@slideshare.net(LMBeharry) 2022-07-15_BIIB_MC-Equity-July-Trials.pdf LMBeharry I valued Biogen back in 2014 for an old friend, and I have looked in on it sporadically over the years. I did not like it back in the 2010s because it had too many competing therapies for multiple schlerosis (from my 2014 report here /LMBeharry/biib-reportlmbenterprises-59573190): " Several of the product offerings address multiple sclerosis, and these pharma products will likely begin cannibalizing each other within the intermediate term. The analyst believes that this cannibalization will curtail growth within the MS product line within the next 18 to 24 months." and " The firm has submitted hemophilia agents, Factor VIII and Factor IX to the US FDA for regulatory review, anticipating marketing approval in 2014-2015. As these hemophilia products are administered orally, analysts expect sales to grow robustly indeed. (i.e. more doctors will prescribe the treatment as it circumvents costly and frequent recurrent need of infusion of clotting factor). Statistics indicate that roughly 20,000 US residents suffer with hemophilia. A market of 20,000 patients is not a growth sector." Note that I have not kept up with its pipeline, nor its successes/failures at clinical trial. This printout is solely an exercise in econometric analysis using its historical cost structure to derive an equity valuation. If you are curious about its current research endeavors, I provide the link for clinical trials here (already sorted for Biogen): https://clinicaltrials.gov/ct2/results?cond=&term=Biogen&cntry=&state=&city=&dist= <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/2022-07-15biibmc-equity-july-trials-220715234449-a537ec54-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> I valued Biogen back in 2014 for an old friend, and I have looked in on it sporadically over the years. I did not like it back in the 2010s because it had too many competing therapies for multiple schlerosis (from my 2014 report here /LMBeharry/biib-reportlmbenterprises-59573190): &quot; Several of the product offerings address multiple sclerosis, and these pharma products will likely begin cannibalizing each other within the intermediate term. The analyst believes that this cannibalization will curtail growth within the MS product line within the next 18 to 24 months.&quot; and &quot; The firm has submitted hemophilia agents, Factor VIII and Factor IX to the US FDA for regulatory review, anticipating marketing approval in 2014-2015. As these hemophilia products are administered orally, analysts expect sales to grow robustly indeed. (i.e. more doctors will prescribe the treatment as it circumvents costly and frequent recurrent need of infusion of clotting factor). Statistics indicate that roughly 20,000 US residents suffer with hemophilia. A market of 20,000 patients is not a growth sector.&quot; Note that I have not kept up with its pipeline, nor its successes/failures at clinical trial. This printout is solely an exercise in econometric analysis using its historical cost structure to derive an equity valuation. If you are curious about its current research endeavors, I provide the link for clinical trials here (already sorted for Biogen): https://clinicaltrials.gov/ct2/results?cond=&amp;term=Biogen&amp;cntry=&amp;state=&amp;city=&amp;dist=
2022-07-15_BIIB_MC-Equity-July-Trials.pdf from Lyndon Martin W. Beharry
]]> 8 0 https://cdn.slidesharecdn.com/ss_thumbnails/2022-07-15biibmc-equity-july-trials-220715234449-a537ec54-thumbnail.jpg?width=120&height=120&fit=bounds document Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 2022-07-15_LMT_MC-Equity_July-2022-Trials.pdf /slideshow/20220715lmtmcequityjuly2022trialspdf/252195370 2022-07-15lmtmc-equityjuly-2022-trials-220715153212-a773ca65
Lockheed Martin Corporation Monte Carlo econometric Equity per Share Valuation; Statistics Only]]>
Lockheed Martin Corporation Monte Carlo econometric Equity per Share Valuation; Statistics Only]]> Fri, 15 Jul 2022 15:32:12 GMT /slideshow/20220715lmtmcequityjuly2022trialspdf/252195370 LMBeharry@slideshare.net(LMBeharry) 2022-07-15_LMT_MC-Equity_July-2022-Trials.pdf LMBeharry Lockheed Martin Corporation Monte Carlo econometric Equity per Share Valuation; Statistics Only <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/2022-07-15lmtmc-equityjuly-2022-trials-220715153212-a773ca65-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> Lockheed Martin Corporation Monte Carlo econometric Equity per Share Valuation; Statistics Only
2022-07-15_LMT_MC-Equity_July-2022-Trials.pdf from Lyndon Martin W. Beharry
]]> 42 0 https://cdn.slidesharecdn.com/ss_thumbnails/2022-07-15lmtmc-equityjuly-2022-trials-220715153212-a773ca65-thumbnail.jpg?width=120&height=120&fit=bounds document Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 2022-07-13_AAPL-MC-Equity_July-2022-Trials.pdf /slideshow/20220713aaplmcequityjuly2022trialspdf/252180563 2022-07-13aapl-mc-equityjuly-2022-trials-220714075626-fd97aa81
Apple Inc. (AAPL) Financial-Accounting / Econometric Summary of operations Running 14 years Showing 10 Monte Carlo DCF Iterations]]>
Apple Inc. (AAPL) Financial-Accounting / Econometric Summary of operations Running 14 years Showing 10 Monte Carlo DCF Iterations]]> Thu, 14 Jul 2022 07:56:26 GMT /slideshow/20220713aaplmcequityjuly2022trialspdf/252180563 LMBeharry@slideshare.net(LMBeharry) 2022-07-13_AAPL-MC-Equity_July-2022-Trials.pdf LMBeharry Apple Inc. (AAPL) Financial-Accounting / Econometric Summary of operations Running 14 years Showing 10 Monte Carlo DCF Iterations <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/2022-07-13aapl-mc-equityjuly-2022-trials-220714075626-fd97aa81-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> Apple Inc. (AAPL) Financial-Accounting / Econometric Summary of operations Running 14 years Showing 10 Monte Carlo DCF Iterations
2022-07-13_AAPL-MC-Equity_July-2022-Trials.pdf from Lyndon Martin W. Beharry
]]> 28 0 https://cdn.slidesharecdn.com/ss_thumbnails/2022-07-13aapl-mc-equityjuly-2022-trials-220714075626-fd97aa81-thumbnail.jpg?width=120&height=120&fit=bounds document Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 2022-BeharryLyndonMartinW-CV-References.pdf /slideshow/2022beharrylyndonmartinwcvreferencespdf/251728625 2022-beharrylyndonmartinw-cv-references-220506060410-64b66a64
Beharry, Lyndon Martin W. Curriculum Vitae Updated with Landline/Fax number; includes references]]>
Beharry, Lyndon Martin W. Curriculum Vitae Updated with Landline/Fax number; includes references]]> Fri, 06 May 2022 06:04:09 GMT /slideshow/2022beharrylyndonmartinwcvreferencespdf/251728625 LMBeharry@slideshare.net(LMBeharry) 2022-BeharryLyndonMartinW-CV-References.pdf LMBeharry Beharry, Lyndon Martin W. Curriculum Vitae Updated with Landline/Fax number; includes references <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/2022-beharrylyndonmartinw-cv-references-220506060410-64b66a64-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> Beharry, Lyndon Martin W. Curriculum Vitae Updated with Landline/Fax number; includes references
2022-BeharryLyndonMartinW-CV-References.pdf from Lyndon Martin W. Beharry
]]> 76 0 https://cdn.slidesharecdn.com/ss_thumbnails/2022-beharrylyndonmartinw-cv-references-220506060410-64b66a64-thumbnail.jpg?width=120&height=120&fit=bounds document Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 2022-05-05_AAPL-MC-VLTN.pdf /slideshow/20220505aaplmcvltnpdf/251728595 2022-05-05aapl-mc-vltn-220506055909-f8fd7a3a
AAPL: Apple, Inc. | FEIN: 94-2404110 2022 Monte Carlo Equity Valuation Workbook Printout]]>
AAPL: Apple, Inc. | FEIN: 94-2404110 2022 Monte Carlo Equity Valuation Workbook Printout]]> Fri, 06 May 2022 05:59:09 GMT /slideshow/20220505aaplmcvltnpdf/251728595 LMBeharry@slideshare.net(LMBeharry) 2022-05-05_AAPL-MC-VLTN.pdf LMBeharry AAPL: Apple, Inc. | FEIN: 94-2404110 2022 Monte Carlo Equity Valuation Workbook Printout <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/2022-05-05aapl-mc-vltn-220506055909-f8fd7a3a-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> AAPL: Apple, Inc. | FEIN: 94-2404110 2022 Monte Carlo Equity Valuation Workbook Printout
2022-05-05_AAPL-MC-VLTN.pdf from Lyndon Martin W. Beharry
]]> 41 0 https://cdn.slidesharecdn.com/ss_thumbnails/2022-05-05aapl-mc-vltn-220506055909-f8fd7a3a-thumbnail.jpg?width=120&height=120&fit=bounds document Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 2022 01-28 lmt-mc-equity-wkbk-trial /slideshow/2022-0128-lmtmcequitywkbktrial/251077943 2022-01-28lmt-mc-equity-wkbktrial-220129175844
Lockheed Martin Corporation Monte Carlo Equity Valuation]]>
Lockheed Martin Corporation Monte Carlo Equity Valuation]]> Sat, 29 Jan 2022 17:58:44 GMT /slideshow/2022-0128-lmtmcequitywkbktrial/251077943 LMBeharry@slideshare.net(LMBeharry) 2022 01-28 lmt-mc-equity-wkbk-trial LMBeharry Lockheed Martin Corporation Monte Carlo Equity Valuation <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/2022-01-28lmt-mc-equity-wkbktrial-220129175844-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> Lockheed Martin Corporation Monte Carlo Equity Valuation
2022 01-28 lmt-mc-equity-wkbk-trial from Lyndon Martin W. Beharry
]]> 104 0 https://cdn.slidesharecdn.com/ss_thumbnails/2022-01-28lmt-mc-equity-wkbktrial-220129175844-thumbnail.jpg?width=120&height=120&fit=bounds document 000000 http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 2022 01-04 l-mw_b_exc-report /slideshow/2022-0104-lmwbexcreport/250942766 2022-01-04lmwbexc-report-220104171815
Exelon Draft 3 w/ minor changes in punctuation, some verbiage changes tightening up the prose. -Mostly superficial changes.]]>
Exelon Draft 3 w/ minor changes in punctuation, some verbiage changes tightening up the prose. -Mostly superficial changes.]]> Tue, 04 Jan 2022 17:18:15 GMT /slideshow/2022-0104-lmwbexcreport/250942766 LMBeharry@slideshare.net(LMBeharry) 2022 01-04 l-mw_b_exc-report LMBeharry Exelon Draft 3 w/ minor changes in punctuation, some verbiage changes tightening up the prose. -Mostly superficial changes. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/2022-01-04lmwbexc-report-220104171815-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> Exelon Draft 3 w/ minor changes in punctuation, some verbiage changes tightening up the prose. -Mostly superficial changes.
2022 01-04 l-mw_b_exc-report from Lyndon Martin W. Beharry
]]> 124 0 https://cdn.slidesharecdn.com/ss_thumbnails/2022-01-04lmwbexc-report-220104171815-thumbnail.jpg?width=120&height=120&fit=bounds document 000000 http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 2022 01-03 l-mw_b_exc-report /slideshow/2022-0103-lmwbexcreport/250936723 2022-01-03lmwbexc-report-220103163711
Exelon Equity Valuation Report 2nd Draft]]>
Exelon Equity Valuation Report 2nd Draft]]> Mon, 03 Jan 2022 16:37:11 GMT /slideshow/2022-0103-lmwbexcreport/250936723 LMBeharry@slideshare.net(LMBeharry) 2022 01-03 l-mw_b_exc-report LMBeharry Exelon Equity Valuation Report 2nd Draft <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/2022-01-03lmwbexc-report-220103163711-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> Exelon Equity Valuation Report 2nd Draft
2022 01-03 l-mw_b_exc-report from Lyndon Martin W. Beharry
]]> 97 0 https://cdn.slidesharecdn.com/ss_thumbnails/2022-01-03lmwbexc-report-220103163711-thumbnail.jpg?width=120&height=120&fit=bounds document Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 2021 12-13 l-mw_b_exc-report /slideshow/2021-1213-lmwbexcreport/250879076 2021-12-13lmwbexc-report-211221143403
Exelon Corporation: Nasdaq: EXC equity valuation report First draft hot off the presses (12/20/2021)]]>
Exelon Corporation: Nasdaq: EXC equity valuation report First draft hot off the presses (12/20/2021)]]> Tue, 21 Dec 2021 14:34:03 GMT /slideshow/2021-1213-lmwbexcreport/250879076 LMBeharry@slideshare.net(LMBeharry) 2021 12-13 l-mw_b_exc-report LMBeharry Exelon Corporation: Nasdaq: EXC equity valuation report First draft hot off the presses (12/20/2021) <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/2021-12-13lmwbexc-report-211221143403-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> Exelon Corporation: Nasdaq: EXC equity valuation report First draft hot off the presses (12/20/2021)
2021 12-13 l-mw_b_exc-report from Lyndon Martin W. Beharry
]]> 107 0 https://cdn.slidesharecdn.com/ss_thumbnails/2021-12-13lmwbexc-report-211221143403-thumbnail.jpg?width=120&height=120&fit=bounds document 000000 http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 https://cdn.slidesharecdn.com/profile-photo-LMBeharry-48x48.jpg?cb=1730895596 Lyndon is a family man with varied interests and a range of capability: insurance brokerage / risk management, equity and stock analysis, university and high school pedagogy. His intellectual interests run the gamut from Financial Analysis and Game Theory to System Complexity Dynamics/Monte Carlo modeling to World History to Physics and Quantum Mechanics to Philosophy and History of Religion. www.lmbesllc.com/ https://cdn.slidesharecdn.com/ss_thumbnails/2022-03-31gild-mc-valuationreportdraft03signed-230401140649-e4fe7055-thumbnail.jpg?width=320&height=320&fit=bounds slideshow/20220331gildmcvaluationreportdraft03signedpdf/257075771 2022-03-31_GILD-MC-Val... https://cdn.slidesharecdn.com/ss_thumbnails/2016impcub-proceedings-pdf-230210144633-352ea1a6-thumbnail.jpg?width=320&height=320&fit=bounds slideshow/2016impcubproceedingspdfpdf/255803795 2016_IMPC_UB-Proceedin... https://cdn.slidesharecdn.com/ss_thumbnails/2022-08-21lancequity-valuation1mm-trials-220821150159-43867f1b-thumbnail.jpg?width=320&height=320&fit=bounds slideshow/20220821lancequityvaluation1mmtrialspdf/252632901 2022-08-21_LANC_Equity...